| Literature DB >> 33597808 |
Ahmed Hassan Albelbeisi1, Ali Albelbeisi2, Abdel Hamid El Bilbeisi3, Mahmoud Taleb4, Amirhossein Takian1,5,6, Ali Akbari-Sari1.
Abstract
This review was conducted to assess the capacity of the public sector to prevent and control noncommunicable diseases (NCDs) in low-and middle-income countries (LMIC) based on WHO-PEN standards. A PRISMA systematic search appraisal of PubMed, Scopus, and Embase was conducted during May-2020 for original articles conducted in LMIC and reported the capacity of the public sector to prevent and control NCDs. The country readiness score was calculated as the mean score of items for each domain. The indices were compared to an agreed cutoff at 80% the WHO optimal target of availability of affordable essential medicines and basic technologies required to treat NCDs. The literature search yielded 5 original studies, conducted in twelve countries, and surveyed 304 public health facilities. All countries failed to reach the WHO optimal target of availability of affordable essential medicines and basic technologies. The readiness index score according to WHO-PEN standards among countries in terms of essential medicines, diagnostic investigations, and basic equipment were range from 13.5% to 51%, 0.0% to 59.4%, and 29.2% to 51.2% respectively. This review revealed critical gaps in the twelve LMIC public sector capacity to prevent and control of NCDs in terms of essential medicines, basic equipment, and diagnostic investigations.Entities:
Keywords: Health facilities; a systematic review; low- and middle-income countries; non-communicable diseases; public sector
Year: 2021 PMID: 33597808 PMCID: PMC7863145 DOI: 10.1177/1178632920986233
Source DB: PubMed Journal: Health Serv Insights ISSN: 1178-6329
Figure 1.Results of the systematic literature search.
Electronic search strategy.
| PubMed, May 2020, Results: 43 |
| (((“(Non communicable Diseases/classification”[Mesh] OR “Non communicable Diseases/drug therapy”[Mesh] OR “Non communicable Diseases/organization and administration”[Mesh] OR “Non communicable Diseases/prevention and control”[Mesh] OR “Non communicable Diseases/therapy”[Mesh]))) OR “NCDs/diagnostic investigations”) OR “NCDs/basic equipment’s”) OR “NCDs/Essential medicines”) OR “NCDs” OR “Non communicable diseases”))) AND (((“Package of essential non communicable diseases interventions”) OR “WHO-PEN”) OR “World Health Organization-Package of essential non communicable diseases interventions”))) |
| Embase, May 2020, Results: 9 |
| #1 (“Non communicable diseases/classification,” OR #2 “Non communicable diseases/drug therapy,” OR #3 “Non communicable diseases/organization and administration,” OR #4 “Non communicable diseases/prevention and control,” OR #5 “Non communicable diseases/therapy,” OR #6 “NCDs/diagnostic investigations,” OR #7 “NCDs/basic equipment’s”, OR #8 “NCDs/essential medicines” OR #9 “NCDs”, OR #10 “Non communicable diseases”), AND # 11 “package of essential non communicable diseases interventions” OR #12 “who-pen,” OR #13 “world health organization-package of essential non communicable diseases interventions”) #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 AND #11 OR #12 OR #13 |
| Scopus, May 2020, Results: 12 |
| (TITLE-ABS-KEY (“NCDs” OR “Non communicable diseases”)) OR (TITLE-ABS-KEY ((“Non communicable Diseases-classification”), OR (“Non communicable Diseases-drug therapy”), OR (“Non communicable Diseases-organization and administration”), OR (“Non communicable Diseases-prevention and control”))) AND (TITLE-ABS-KEY ((“Package of essential non communicable diseases interventions”) OR (“WHO-PEN”) OR (“World Health Organization-Package of essential non communicable diseases interventions”))) |
Characteristics of the included studies.
| Authors name | Year of publication | Country | World bank income class | Study design | Sample size | Facilities type | ||
|---|---|---|---|---|---|---|---|---|
| PHC | Other | |||||||
| 1. | Mendis et al[ | 2012 | Benin | Low income | Cross sectional | 12 | 12 (100) | 0 (0.00) |
| Eritrea | Low income | Cross sectional | 6 | 6 (100) | 0 (0.00) | |||
| Sudan | Lower middle | Cross sectional | 12 | 12 (100) | 0 (0.00) | |||
| Syria | Low income | Cross sectional | 14 | 14 (100) | 0 (0.00) | |||
| Bhutan | Lower middle | Cross sectional | 7 | 7 (100) | 0 (0.00) | |||
| Sri Lanka | Upper-middle | Cross sectional | 14 | 14 (100) | 0 (0.00) | |||
| Vietnam | Lower middle | Cross sectional | 15 | 15 (100) | 0 (0.00) | |||
| Suriname | Upper middle | Cross sectional | 10 | 10 (100) | 0 (0.00) | |||
| 2. | Nyarko et al[ | 2016 | Ghana | Lower middle | Cross sectional | 23 | 18 (78.3) | 3 (13.0) |
| 2 (8.7) | ||||||||
| 3. | Aryal et al[ | 2018 | Nepal | Low income | Cross sectional | 92 | 8 (8.7) | 3 (3.3) |
| 81 (88.0) | ||||||||
| 4. | Mutale et al[ | 2018 | Zambia | Lower middle | Cross sectional | 46 | 43 (93.5) | 3 (6.5) |
| 5. | Rogers et al[ | 2018 | Ugandan | Low income | Cross sectional | 53 | 14 (26.4) | 26 (49.0) |
| 13 (24.5) | ||||||||
The World Bank. Country and Lending Groups by Income, available at: http://data.worldbank.org/about/country-classifications/country-and-lending-groups.
Abbreviation: PHC, primary health care.
Other: *District hospital.
Regional Hospitals.
Health post.
1sth level hospitals.
General Hospital.
Percentage availability of essential medicines in health facilities in defined areas in twelve countries and readiness index score by country.
| Variables | Benin ( | Eritrea ( | Sudan ( | Syria ( | Bhutan ( | Sri Lanka ( | Vietnam ( | Suriname ( | Ghana ( | Nepal ( | Zambia ( | Ugandan ( |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Adrenaline | NA | NA | NA | NA | NA | NA | NA | NA | 47.8 | 34.8 | 71.7 | NA |
| 2. Atenolol | 8.3 | 0.0 | 42.9 | 14.3 | 0.0 | 69.2 | 93.3 | 100.0 | 26.1 | 65.2 | 28.3 | 64.2 |
| 3. Enalapril | 33.3 | 0.0 | 28.6 | 14.3 | 0.0 | 69.2 | 60.0 | 30.0 | 26.1 | 0.0 | 6.5 | 67.9 |
| 4. Amlodipine | 58.3 | 0.0 | 50.0 | 0.0 | 0.0 | 69.2 | 86.7 | 80.0 | 65.2 | 65.2 | 23.9 | 90.6 |
| 5. Hydrochlorothiazide | 75.0 | 100.0 | 35.7 | 14.3 | 85.7 | 69.2 | 40.0 | 90.0 | 26.1 | 35.9 | NA | 83.0 |
| 6. Isosorbide dinitrate | 0.0 | 0.0 | 0.0 | 21.4 | 0.0 | 69.2 | 60.0 | 90.0 | 17.4 | NA | NA | 73.6 |
| 7. Frusemide (other | 83.3 | 50.0 | 85.7 | 92.9 | 14.3 | 69.2 | 86.7 | 100.0 | 34.8 | NA | 58.7 | 73.6 |
| 8. Simvastatin or lovastatin | 8.3 | 0.0 | 35.7 | 7.1 | 0.0 | 23.1 | 46.7 | 50.0 | 13.0 | 0.0 | 0.0 | NA |
| 9. Insulin long acting | 0.0 | 0.0 | 21.4 | 21.4 | 0.0 | 30.8 | 0.0 | 80.0 | 17.4 | NA | 17.4 | 52.8 |
| Insulin soluble | 0.0 | 0.0 | 28.6 | 21.4 | 0.0 | 30.8 | 0.0 | 80.0 | 21.7 | NA | 21.7 | 52.8 |
| 10. Metformin | 25.0 | 0.0 | 42.9 | 14.3 | 0.0 | 69.2 | 53.3 | 100.0 | 26.1 | 47.8 | 45.7 | 92.3 |
| 11. Glibenclamide | 41.7 | 0.0 | 71.4 | 21.4 | 14.3 | 69.2 | 33.3 | 100.0 | 26.1 | 0.0 | 45.7 | 81.1 |
| 12. Beclometasone inhaler | 33.3 | 16.7 | 21.4 | 28.6 | 0.0 | 15.4 | 6.7 | 80.0 | 17.4 | NA | NA | NA |
| 13. Prednisolone | 0.0 | 0.0 | 42.9 | 7.1 | 0.0 | 69.2 | 93.3 | 90.0 | 39.1 | NA | 95.7 | NA |
| 14. Salbutamol inhaler | 33.3 | 100.0 | 71.4 | 78.6 | 0.0 | 30.8 | 20.0 | 90.0 | 39.1 | NA | 73.9 | NA |
| Salbutamol tablets | 66.7 | 100.0 | 85.7 | 14.3 | 100.0 | 69.2 | 93.3 | 90.0 | 65.2 | 92.4 | NA | NA |
| Salbutamol injectable | NA | NA | NA | NA | NA | NA | NA | NA | 17.4 | NA | NA | NA |
| 15. Ipratropium bromide | 0.0 | 0.0 | 14.3 | 14.3 | 0.0 | 30.8 | 0.0 | 20.0 | 4.3 | NA | NA | NA |
| 16. Aspirin | 100.0 | 100.0 | 100.0 | 21.4 | 0.0 | 69.2 | 100.0 | 100.0 | 82.6 | 65.2 | 67.4 | NA |
| 17. Paracetamol | 100.0 | 100.0 | 92.0 | 0.0 | 100.0 | 69.2 | 100.0 | 100.0 | 100.0 | NA | 78.3 | NA |
| 18. Ibuprofen | 83.3 | 100.0 | 100.0 | 0.0 | 100.0 | 69.2 | 73.3 | 80.0 | 100.0 | NA | 78.3 | NA |
| 19. Morphine (oral) | 0.0 | 0.0 | 14.3 | 0.0 | 0.0 | 15.4 | 0.0 | 20.0 | 8.7 | NA | NA | NA |
| Morphine injection | 8.3 | 0.0 | 14.3 | 0.0 | 0.0 | 38.5 | 0.0 | 20.0 | 13.0 | NA | NA | NA |
| 20. Codeine | 8.3 | 0.0 | 35.7 | 0.0 | 0.0 | 15.4 | 33.3 | 60.0 | 13.0 | NA | NA | NA |
| 21. Glucose solution for injection | 91.7 | 0.0 | 0.0 | 0.0 | 57.1 | 53.8 | 66.7 | 80.0 | 86.9 | NA | 82.6 | NA |
| 22. Sodium chloride infusion | 91.7 | 100.0 | 92.9 | 35.7 | 0.0 | 53.8 | 100.0 | 60.0 | 91.3 | NA | 84.8 | NA |
| 23. Benzathine penicillin | 50.0 | 100.0 | 92.9 | 57.1 | 30.8 | 0.0 | 60.0 | 100.0 | 69.6 | NA | 95.7 | NA |
| 24. Erythromycin | NA | NA | NA | NA | NA | NA | NA | NA | 73.9 | NA | 95.7 | NA |
| 25. Amoxicillin | NA | NA | NA | NA | NA | NA | NA | NA | 100 | NA | 95.7 | NA |
| 26. Hydrocortisone (steroids) | NA | NA | NA | NA | NA | NA | NA | NA | 91.3 | NA | 95.7 | NA |
| 27. Heparin | NA | NA | NA | NA | NA | NA | NA | NA | 21.7 | NA | NA | NA |
| 28. Diazepam | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 29. Magnesium sulphate | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 73.6 |
| 30. Promethazine | NA | NA | NA | NA | NA | NA | NA | NA | 82.6 | NA | 91.3 | NA |
| 31. Senna | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 32. Glyceryl trinitrate | NA | NA | NA | NA | NA | NA | NA | NA | 8.7 | NA | 6.5 | NA |
| 33. Spironolactone | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Readiness index score for WHO-PEN items included in the study | 39.9 | 34.8 | 48.9 | 20.0 | 20.1 | 43.9 | 52.3 | 75.6 | 44.6 | 40.7 | 59.2 | 73.23 |
| Readiness index score, WHO-PEN standard | 27.0 | 23.4 | 33.0 | 13.5 | 13.6 | 29.7 | 35.3 | 51.0 | 39.8 | 10.9 | 36.8 | 21.8 |
Data are expressed as percentage for different categorical variables.
Abbreviation: NA: Not available in the study survey.
Percentage availability of basic diagnostic tests in health facilities in defined areas in twelve countries and readiness index score by country.
| Variables | Benin ( | Eritrea ( | Sudan ( | Syria ( | Bhutan ( | Sri Lanka ( | Vietnam ( | Suriname ( | Ghana ( | Nepal ( | Zambia ( | Ugandan ( |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Urine albumin | 100 | 67 | 92 | 64 | 100 | 46 | 0.0 | 70 | 34.8 | NA | NA | 13.2 |
| 2. Urine glucose | 92 | 67 | 92 | 71 | 100 | 54 | 0.0 | 70 | 34.8 | NA | NA | 92.5 |
| 3. Urine ketones | 42 | 33 | 58 | 79 | 0.0 | 0.0 | 0.0 | 40 | 26.1 | NA | NA | 92.5 |
| 4. Blood glucose | 67 | 17 | 75 | 93 | 0.0 | 0.0 | 0.0 | 90 | 26.1 | NA | NA | 92.5 |
| 5. Blood cholesterol | 25 | 0.0 | 33 | 14 | 0.0 | 8.0 | 0.0 | 20 | 17.4 | NA | NA | 28.3 |
| 6. Serum creatinine | 33 | 0.0 | 58 | 0.0 | 0.0 | 8.0 | 0.0 | 10 | 17.4 | NA | NA | 43.4 |
| 7. Serum troponin | 8.0 | 0.0 | 8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | NA | NA | NA |
| Readiness index score for WHO-PEN items included in the study | 52.4 | 26.3 | 59.4 | 45.9 | 28.6 | 16.6 | 0.0 | 42.9 | 22.4 | NA | 74.2 | 60.4 |
| Readiness index score, WHO-PEN standard | 52.4 | 26.3 | 59.4 | 45.9 | 28.6 | 16.6 | 0.0 | 42.9 | 22.4 | NA | NA | 51.8 |
Data are expressed as percentage for different categorical variables.
Abbreviation: NA: Not available in the study survey.
Percentage availability of basic equipment in health facilities in defined areas in twelve countries and readiness index score by country.
| Equipment | Benin ( | Eritrea ( | Sudan ( | Syria ( | Bhutan ( | Sri Lanka (n = 14) | Vietnam ( | Suriname ( | Ghana ( | Nepal ( | Zambia ( | Ugandan ( |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Blood pressure devices (Mercury) | 100 | 100 | 97.8 | NA | 39.6 | |||||||
| 2. Oxygen cylinders or masks | 44 | 26.1 | 10.9 | NA | NA | |||||||
| 3. Weighing machines | 99 | 100 | 98.9 | NA | 56.6 | |||||||
| 4. Stethoscope | NA | 100 | 98.9 | NA | 58.5 | |||||||
| 5. Thermometer | NA | 100 | 98.9 | NA | 54.7 | |||||||
| 6. Measuring tape | 63 | 87.0 | 90.2 | NA | 50.9 | |||||||
| 7. Health education material | NA | 43.5 | NA | NA | 15.1 | |||||||
| 8. Nebulizers | 37 | 26.1 | 35.9 | NA | 15.1 | |||||||
| 9. Electrocardiographs | 28 | 17.4 | 7.6 | NA | 15.1 | |||||||
| 10. Peak flow meters | 20 | 13.0 | NA | NA | 1.9 | |||||||
| 11. Pulse oximeter | 2 | 26.1 | 13.0 | NA | NA | |||||||
| 12. Spacer | NA | 0.0 | 19.6 | NA | 9.4 | |||||||
| 13. Glucometer | NA | 26.1 | 89.1 | NA | 62.3 | |||||||
| Readiness index score for WHO-PEN items included in the study | 49.1 | 51.2 | 60.1 | 57.6 | 34.5 | |||||||
| Readiness index score, WHO-PEN standard | 30.2 | 51.2 | 50.8 | NA | 29.2 | |||||||
Data are expressed as percentage for different categorical variables.
Abbreviation: NA: Not available in the study survey.
Readiness index score, WHO-PEN standard for primary healthcare centers.
| Country | Primary healthcare centers | Essential medicines | Basic diagnostic tests | Basic equipment’s |
|---|---|---|---|---|
| Benin | 12.0 (100) | 27.0 | 52.4 | 30.2 |
| Eritrea | 6.0 (100) | 23.4 | 26.3 | 30.2 |
| Sudan | 12.0 (100) | 33.0 | 59.4 | 30.2 |
| Syria | 14.0 (100) | 13.5 | 45.9 | 30.2 |
| Bhutan | 7.0 (100) | 13.6 | 28.6 | 30.2 |
| Sri Lanka | 14.0 (100) | 29.7 | 16.6 | 30.2 |
| Vietnam | 15.0 (100) | 35.3 | 0.0 | 30.2 |
| Suriname | 10.0 (100) | 51.0 | 42.9 | 30.2 |
| Ghana | 18.0 (78.3) | 31.5 | 6.3 | 41.4 |
| Nepal | 8.0 (8.7) | 17.0 | NA | 69.2 |
| Zambia | 43.0 (93.5) | NA | NA | NA |
| Ugandan | 14.0 (26.4) | 21.2 | 42.9 | 26.4 |
Data are expressed as percentage for different categorical variables.
Abbreviation: NA: Not available in the study survey.